Abstract
The pi3k/Akt/mtor (phosphatidylinositol 3 kinase/ Akt/mammalian target of rapamycin) signalling pathway is an established driver of oncogenic activity in human malignancies. Therapeutic targeting of this pathway holds significant promise as a treatment strategy. Everolimus, an mtor inhibitor, is the first of this class of agents approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Everolimus has been associated with significant improvements in progression-free survival; however, it is also associated with increased toxicity related to its specific mechanism of action. A comprehensive review of the literature conducted using a focused medline search was combined with a search of current trials at http://ClinicalTrials.gov/. Summary tables of the toxicities of the various classes of pi3k/Akt/mtor inhibitors were created. A broad group of Canadian health care professionals was assembled to review the data and to produce expert opinion and summary recommendations for possible best practices in managing the adverse events associated with these pathway inhibitors. Differing toxicities are associated with the various classes of pi3k/Akt/mtor pathway inhibitors. The most common unique adverse events observed in everolimus clinical trials in breast cancer include stomatitis (all grades: approximately 60%), noninfectious pneumonitis (15%), rash (40%), hyperglycemia (15%), and immunosuppression (40%). To minimize grades 3 and 4 toxicities and to attempt to attain optimal outcomes, effective management of those adverse events is critical. Management should be interdisciplinary and should use approaches that include education, early recognition, active intervention, and potentially prophylactic strategies. Everolimus likely represents the first of many complex oral targeted therapies for the treatment of breast cancer. Using this agent as a template, it is essential to establish best practices involving and integrating multiple disciplines for the management of future pi3k/Akt/mtor signalling pathway inhibitors.
Highlights
The pi3k/Akt/mtor signalling cascade is well characterized and plays crucial roles in a variety of physiologic processes (Figure 1): cell cycle progression, differentiation, transcription, translation, apoptosis, motility, autophagy, anabolic processes, and metabolic processes[1]
The most common unique adverse events observed in everolimus clinical trials in breast cancer include stomatitis, noninfectious pneumonitis (15%), rash (40%), hyperglycemia (15%), and immunosuppression (40%)
“pathway,” “breast cancer,” “metabric,” “tcga,” “aberrations,” “inhibition,” “mechanism,” “toxicity,” “adverse events,” “everolimus,” “intervention,” “management,” “education,” “patient,” and “stomatitis.” In addition, the proceedings of the 2013–2014 American Society of Clinical Oncology and the 2013–2014 European Society for Medical Oncology annual meetings were searched for abstract reports of relevant studies
Summary
The pi3k/Akt/mtor (phosphatidylinositol 3 kinase/ Akt/mammalian target of rapamycin) signalling cascade is well characterized and plays crucial roles in a variety of physiologic processes (Figure 1): cell cycle progression, differentiation, transcription, translation, apoptosis, motility, autophagy, anabolic processes (including protein and lipid synthesis), and metabolic processes (including normal glucose homeostasis)[1]. Activation of the pi3k/Akt/ mtor signalling pathway in breast cancer could be as frequent as 70%, and some studies suggest that its activation is associated with aggressive features such as high histologic grade, the basal-like and her[2] phenotypes, and poor clinical outcome[7]. Pi3k = phosphatidylinositol 3 kinase; pip = phosphatidylinositol-4 phosphate; pten = phosphatase and tensin homolog; cic = cancer-initiating cell; Akt = v-akt murine thymoma viral oncogene; mtor = mammalian target of rapamycin; tsc = tuberous sclerosis; s6k = S6 kinase; 4ebp1 = 4E-binding protein. Activation of the pi3k pathway has been implicated in resistance to hormonal therapy, and inhibition of mtor has been associated with restoration of hormone sensitivity, when inhibitors are given in combination with hormonal agents[9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
